| Literature DB >> 33637716 |
Fang Zheng1,2, Jianing Chen1,3, Xiaoqian Zhang3, Zifeng Wang4, Jiewen Chen3, Xiaorong Lin3, Hongyan Huang5, Wenkui Fu6, Jing Liang7, Wei Wu1,3, Bo Li1, Herui Yao1,6, Hai Hu8,9, Erwei Song10,11,12,13.
Abstract
Hypoxia-inducible factor-1 (HIF-1) is a master driver of glucose metabolism in cancer cells. Here, we demonstrate that a HIF-1α anti-sense lncRNA, HIFAL, is essential for maintaining and enhancing HIF-1α-mediated transactivation and glycolysis. Mechanistically, HIFAL recruits prolyl hydroxylase 3 (PHD3) to pyruvate kinase 2 (PKM2) to induce its prolyl hydroxylation and introduces the PKM2/PHD3 complex into the nucleus via binding with heterogeneous nuclear ribonucleoprotein F (hnRNPF) to enhance HIF-1α transactivation. Reciprocally, HIF-1α induces HIFAL transcription, which forms a positive feed-forward loop to maintain the transactivation activity of HIF-1α. Clinically, high HIFAL expression is associated with aggressive breast cancer phenotype and poor patient outcome. Furthermore, HIFAL overexpression promotes tumor growth in vivo, while targeting both HIFAL and HIF-1α significantly reduces their effect on cancer growth. Overall, our results indicate a critical regulatory role of HIFAL in HIF-1α-driven transactivation and glycolysis, identifying HIFAL as a therapeutic target for cancer treatment.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33637716 PMCID: PMC7910558 DOI: 10.1038/s41467-021-21535-3
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919